ReviewPharmacoEconomics1996
Statistical analysis in pharmacoeconomic studies. A review of current issues and standards.
Review in PharmacoEconomics, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Using social media to deliver weight loss programming to young adults: Design and rationale for the Healthy Body Healthy U (HBHU) trial.Contemporary clinical trials · 2017Trial
- Using cost of infection as a tool to demonstrate a difference in prophylactic antibiotic efficacy: a prospective randomized comparison of the pharmacoeconomic effectiveness of ceftriaxone and cefotaxime prophylaxis in abdominal surgery.World journal of surgery · 2005Trial
- Cost effectiveness of interventions for lateral epicondylitis: results from a randomised controlled trial in primary care.PharmacoEconomics · 2004Trial
- Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial.PharmacoEconomics · 2002Trial
- Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease.PharmacoEconomics · 1999Trial
- Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.PharmacoEconomics · 1999Trial
- Economic evaluations: a new avenue of outcome assessment in spinal disorders.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2006Review
- How should cost data in pragmatic randomised trials be analysed?BMJ (Clinical research ed.) · 2000Review
- Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.PharmacoEconomics · 2000Review
- Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui Farmaci.PharmacoEconomics · 1999Article
- Analysis and interpretation of cost data in randomised controlled trials: review of published studies.BMJ (Clinical research ed.) · 1998Review
- Common errors and controversies in pharmacoeconomic analyses.PharmacoEconomics · 1998Review
- The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data.PharmacoEconomics · 1998Review
- Use of confidence intervals in health economic studies.PharmacoEconomics · 1996Article
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing number of economic evaluations of healthcare interventions, and of drug therapies in particular, has been well documented. However, surveys have demonstrated that standards of conduct of such studies have not similarly increased. Of particular concern is the lack of development or even consideration of statistical techniques in the reporting of studies. This article addresses issues that must be considered both in the conduct and in the assessment of the quality of studies. Throughout the paper, examples of pharmacoeconomic analyses are used to illustrate the points made. Recommendations for the conduct of future pharmacoeconomic studies are given. Such recommendations specifically relate to the level of testing that is conducted, the choice of statistical tests and the manner in which statistical significance is reported. In addition, existing methods for the statistical analysis of cost-effectiveness ratios and for the determination of sample size in economic evaluations are discussed, and a partial solution to this issue is offered.
Indexed as
Identifiers
10160478What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.